Brokerages Set Haemonetics Co. (NYSE:HAE) Price Target at $101.22

Shares of Haemonetics Co. (NYSE:HAE - Get Free Report) have received an average rating of "Moderate Buy" from the nine analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $101.22.

HAE has been the topic of several analyst reports. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and cut their target price for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Raymond James reaffirmed a "strong-buy" rating and issued a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. StockNews.com cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. JMP Securities lowered their target price on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. Finally, JPMorgan Chase & Co. assumed coverage on Haemonetics in a research report on Friday, December 6th. They set an "overweight" rating and a $116.00 price target on the stock.

Remove Ads

Haemonetics Stock Down 3.0 %

Shares of HAE traded down $1.91 during mid-day trading on Monday, hitting $62.13. The company's stock had a trading volume of 761,334 shares, compared to its average volume of 667,862. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The company's 50-day moving average is $65.21 and its 200-day moving average is $74.38. Haemonetics has a 52-week low of $58.80 and a 52-week high of $97.97. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, equities research analysts forecast that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Trading of Haemonetics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cerity Partners LLC lifted its holdings in shares of Haemonetics by 31.1% during the third quarter. Cerity Partners LLC now owns 8,855 shares of the medical instruments supplier's stock worth $712,000 after purchasing an additional 2,102 shares during the period. FMR LLC raised its position in Haemonetics by 206.3% during the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier's stock worth $62,257,000 after buying an additional 521,640 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Haemonetics by 174.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier's stock valued at $1,362,000 after acquiring an additional 10,774 shares during the period. Captrust Financial Advisors boosted its holdings in shares of Haemonetics by 30.1% in the 3rd quarter. Captrust Financial Advisors now owns 4,248 shares of the medical instruments supplier's stock valued at $341,000 after acquiring an additional 982 shares during the last quarter. Finally, Paloma Partners Management Co purchased a new stake in shares of Haemonetics in the 3rd quarter valued at $623,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.